Researchers will compare IMT capsules and Placebo to investigate the change in gut microbiota diversity. conditions: Acute Lymphoblastic Leukaemia conditions: Acute Leukemia of Ambiguous Lineage conditions: Chronic Myeloid Leukemia conditions: Chronic Myelomonocytic Leukemia conditions: Myelodysplastic Syndrome conditions: Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 50 type: ESTIMATED name: EBX-102 name: Placebo measure: Change in gut microbiota diversity using Inverse Simpsons Index measure: Gut Microbiome Diversity - Alpha diversity measure: Alpha Diversity - Chao1 Index measure: Alpha Diversity - Shannon Index measure: Alpha Diversity - Faiths Phylogenetic Diversity (Faiths PD) measure: Beta Diversity - Aitchison Distance measure: Gut Microbiome Taxonomic Composition measure: Markers of general health - ITU Admission measure: Quality of life EQ-5D-5L measure: Quality of Life EORTC-QLQ-C30 measure: Infective Haematological Outcomes - Fever Occurrence measure: Infective Haematological Outcomes - Fever CTCAE Grade measure: Infective Haematological Outcomes - Infection measure: Infective Haematological Outcomes - Multi drug Resistant Bacterial Colonisation (MDROs) measure: Infective Haematological Outcomes - Antibiotic Use measure: Markers of General Health - Severity of Mucositis measure: Markers of General Health -Occurrence of Severe Acute Kidney Injury (AKI) measure: Markers of General Health - Occurrence of Severe liver dysfunction measure: Markers of general health - Use of Parenteral Nutrition measure: Neutrophil and platelet engraftment data measure: Recovery of T-cell Chimaerisms, measure: Haematological Outcomes - Non-relapsed mortality measure: Haematological Outcomes - Occurrence Graft vs Host Disease measure: Haematological Outcomes - Severity of graft vs Host Disease measure: Overall Survival measure: Graft-versus disease-free relapse-free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospitals Birmingham NHS Foundation Trust city: Birmingham state: England zip: B15 2WB country: United Kingdom name: Senior Haematology Research Sister role: CONTACT phone: 01213714351 email: HaematologyCancerResearch@uhb.nhs.uk name: Francesca Kinsella role: PRINCIPAL_INVESTIGATOR lat: 52.48142 lon: -1.89983 facility: Leeds Teaching Hospital NHS Trust city: Leeds state: England zip: LS9 7TF country: United Kingdom name: Principal Investigator role: CONTACT phone: 01132068561 email: anjum.khan@nhs.net lat: 53.79648 lon: -1.54785 facility: University College London Hospitals NHS Trust city: London state: England zip: NW1 2BU country: United Kingdom name: BMT Trials role: CONTACT email: uclh.bmttrials@nhs.net name: Panagiotis Kottaridis role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 facility: Kings College NHS Foundation Trust city: London state: England zip: SE5 9RS country: United Kingdom name: Principal Investigator role: CONTACT email: p.krishnamurthy@nhs.net name: Pramila Krishnamurthy role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 facility: Imperial College Healthcare NHS Trust city: London state: England zip: W12 0NN country: United Kingdom name: Senior Research Operations Manager role: CONTACT phone: 02037048452 email: Eleni.Vourvou@nhs.net lat: 51.50853 lon: -0.12574 facility: Royal Mardsen Hostpital city: London zip: SW3 6JJ country: United Kingdom name: Haemato-Oncology Department role: CONTACT phone: 0208915 6187 email: Emma.Nicholson@rmh.nhs.uk name: Emma Nicholson role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 hasResults: False